Compare Crispr Therapeutics AG (CRSP) vs Dollar Tree, Inc. (DLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Dollar Tree, Inc. — how do they compare? Crispr Therapeutics AG trades at $52.86 (market cap $4.88B), while Dollar Tree, Inc. trades at $117.68 (market cap $22.26B). The key difference: Dollar Tree, Inc. is far larger — about 4.6× Crispr Therapeutics AG's market cap, and Dollar Tree, Inc. is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Dollar Tree, Inc. for 58 Days on average.
| CRSP | DLTR | |
|---|---|---|
Market Cap | $4.88B | $22.26B |
Volume | 2,861,747 | 2,317,428 |
Sector | Health | Consumer Staples |
52-Week High | $74.92 | $141.21 |
52-Week Low | $44.34 | $86.80 |
Typical Hold Time | 77 Days | 58 Days |
Enterprise Value | $3.30B | $28.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
Dollar Tree (DLTR) trades at $116.30, up 0.09% with a bullish technical signal despite bearish moving averages. The company shows strong earnings beats in recent quarters with Q2 2026 EPS of $2.70 beating expectations of $1.15. Revenue trends show recovery from 2025's $17.58B to projected $20.1B in 2026, while net income rebounds from -$3.03B to projected $1.6B. Analyst consensus is bullish with 53% buy ratings and $139.33 price target, representing 20% upside potential.
DLTR presents a compelling investment case with improving fundamentals and positive earnings momentum, though margin pressures and tariff volatility remain key risks. The stock's attractive valuation (P/E 14.54, EV/EBITDA 9.91) combined with strategic initiatives and store expansions support growth outlook, but investors should monitor cost inflation and competitive pressures in the discount retail sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →
